A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 10, 2015, Pages 1226-1233

  Reinisch, Walter ^a,e   Altorjay, Istvan ^b   Zsigmond, Ferenc ^c   Primas, Christian ^a   Vogelsang, Harald ^a   Novacek, Gottfried ^a   Reinisch, Sieglinde ^a,e   Thomsen, Lars L ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Military Hospital   (Hungary)

^d Pharmacosmos AS   (Denmark)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

anemia; inflammatory bowel disease; intravenous iron; iron deficiency

Indexed keywords

GASTROINTESTINAL AGENT; HEMOGLOBIN; IRON DERIVATIVE; IRON ISOMALTOSIDE; UNCLASSIFIED DRUG; DISACCHARIDE; FERRIC ION; IRON ISOMALTOSIDE 1000;

ADULT; AGED; ALGORITHM; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY ANEMIA; IRON THERAPY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANEMIA, IRON-DEFICIENCY; AUSTRIA; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HUNGARY; INFLAMMATORY BOWEL DISEASES; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; RISK ASSESSMENT; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; ANEMIA, IRON-DEFICIENCY; AUSTRIA; DISACCHARIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRIC COMPOUNDS; FOLLOW-UP STUDIES; HUMANS; HUNGARY; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937150491     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1031168     Document Type: Article

References (17)

1. Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease-a practical approach. Ann Gastroenterol 2013;26:104-13.
2. Gisbert JP, Bermejo F, Pajares R, Perez-Calle JL, Rodriguez M, Algaba A, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis 2009;15:1485-91.
3. Gomollon F, Gisbert JP. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009;15:4659-65.
4. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006;12:123-30.
5. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190-7.
6. Goldberg ND. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2013; 6:61-70.
7. Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, et al. A randomized, openlabel, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013;108: 1877-88.
8. Reinisch W, Chowers Y, Danese S, Dignass A, Gomollon F, Nielsen OH, et al. The management of iron deficiency in inflammatory bowel disease-an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013;38:1109-18.
9. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and metaanalysis. J Crohns Colitis 2012;6:267-75.
10. Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009;104:1460-7.
11. Gauche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:1545-53.
12. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103:1182-92.
13. Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:269-77.
14. Munoz M, Gomez-Ramirez S, Garcia-Erce JA. Intravenous iron in inflammatory bowel disease. World J Gastroenterol 2009;15:4666-74.
15. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141: 846-53.
16. Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 2000;46:IV1-5.
17. Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med 2014;72: 49-53.